相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
1
100.0%
暂无批准数据
- TB Alliance will present clinical trial results for sorfequiline (TBAJ-876), a next-generation diarylquinoline antibiotic, at the World Conference on Lung Health in Copenhagen on November 19, 2025. - The NC-009 phase 2 trial evaluated sorfequiline combined with pretomanid and linezolid across 22 sites in five countries, comparing efficacy and safety against standard TB treatments. - Earlier trial results demonstrated that sorfequiline has a better safety profile than bedaquiline and potential to treat bedaquiline-resistant tuberculosis strains. - The drug candidate represents a potential advancement in addressing the urgent need for novel TB regimens to combat emerging drug resistance and shorten treatment duration.
- The price of pretomanid, a critical component of drug-resistant tuberculosis treatment, has fallen to $169 per course, down from $364 in 2019, making it available for less than $1 per day. - TB Alliance's multi-manufacturer strategy has successfully created market competition, with Mumbai-based Lupin becoming the third licensed manufacturer to produce the high-quality drug. - The full BPaL/M regimen now costs $310, a 47% reduction since 2022, potentially allowing treatment for an additional 120,000 people with drug-resistant TB annually.
